Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Operating Expenses (2022 - 2025)

Entrada Therapeutics has reported Operating Expenses over the past 4 years, most recently at $43.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $43.5 million for Q4 2025, up 0.56% from a year ago — trailing twelve months through Dec 2025 was $183.3 million (up 11.94% YoY), and the annual figure for FY2025 was $183.3 million, up 11.94%.
  • Operating Expenses for Q4 2025 was $43.5 million at Entrada Therapeutics, down from $48.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for TRDA hit a ceiling of $48.8 million in Q2 2025 and a floor of $22.2 million in Q1 2022.
  • Median Operating Expenses over the past 4 years was $37.5 million (2023), compared with a mean of $36.0 million.
  • Biggest five-year swings in Operating Expenses: surged 46.17% in 2023 and later grew 0.56% in 2025.
  • Entrada Therapeutics' Operating Expenses stood at $25.6 million in 2022, then surged by 44.43% to $36.9 million in 2023, then rose by 17.11% to $43.3 million in 2024, then increased by 0.56% to $43.5 million in 2025.
  • The last three reported values for Operating Expenses were $43.5 million (Q4 2025), $48.7 million (Q3 2025), and $48.8 million (Q2 2025) per Business Quant data.